Dascena, Inc. is a science and technology company developing algorithms as predictive biomarkers for complex conditions in inpatient and emergency settings.

Our NIH-funded machine learning and clinical research has led to our suite of AlgoDiagnostics for predicting acute decompensation, sepsis and acute kidney injury, resulting in several peer-reviewed publications. Providers across the country use our AlgoDiagnostics on tens of thousands of patients per year to make early, accurate, and often life-saving interventions.